Advertisement
Singapore markets closed

  • Straits Times Index

    3,332.80
    -10.55 (-0.32%)
     

  • Nikkei

    39,583.08
    +241.54 (+0.61%)
     

  • Hang Seng

    17,718.61
    +2.14 (+0.01%)
     

  • FTSE 100

    8,164.12
    -15.56 (-0.19%)
     

  • Bitcoin USD

    60,870.11
    -727.20 (-1.18%)
     

  • CMC Crypto 200

    1,270.38
    -13.45 (-1.05%)
     

  • S&P 500

    5,499.39
    +16.52 (+0.30%)
     

  • Dow

    39,234.14
    +70.08 (+0.18%)
     

  • Nasdaq

    17,920.96
    +62.28 (+0.35%)
     

  • Gold

    2,339.40
    +2.80 (+0.12%)
     

  • Crude Oil

    81.39
    -0.35 (-0.43%)
     

  • 10-Yr Bond

    4.3230
    +0.0350 (+0.82%)
     

  • FTSE Bursa Malaysia

    1,590.09
    +5.15 (+0.32%)
     

  • Jakarta Composite Index

    7,063.58
    +95.63 (+1.37%)
     

  • PSE Index

    6,411.91
    +21.33 (+0.33%)
     

Corcept: Q1 Earnings Snapshot

Associated Press Finance
·1-min read

MENLO PARK, Calif. (AP) — MENLO PARK, Calif. (AP) — Corcept Therapeutics Inc. (CORT) on Wednesday reported first-quarter earnings of $27.5 million.

On a per-share basis, the Menlo Park, California-based company said it had net income of 25 cents.

The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 21 cents per share.

The drug developer posted revenue of $146.8 million in the period, also topping Street forecasts. Four analysts surveyed by Zacks expected $137.8 million.

Corcept expects full-year revenue in the range of $620 million to $650 million.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CORT at https://www.zacks.com/ap/CORT